# Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

> **NCT02414958** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 730 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02414958
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-30
- **Primary completion:** 2017-04-20
- **Final completion:** 2017-10-23
- **Target enrollment:** 730 (ACTUAL)
- **Last updated:** 2019-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02414958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02414958, "Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02414958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*